Regulatory T cells and Autoimmune Diseases

1st Edition - May 22, 2024
Editors: Mitesh Kumar Dwivedi, DeLisa Fairweather
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 9 4 7 - 5
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 9 4 8 - 2

Regulatory T Cells and Autoimmune Diseases addresses recent findings concerning the role of Tregs in the pathogenesis of autoimmune diseases as well as their therapeutic applicati… Read more

Purchase options

World Book Day Celebration!

Save up to 30% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Regulatory T Cells and Autoimmune Diseases addresses recent findings concerning the role of Tregs in the pathogenesis of autoimmune diseases as well as their therapeutic applications. In particular, this book deals with various Treg-based mechanisms that can lead to autoimmune disease and covers different aspects linking Tregs with autoimmune mechanisms involved in disease development by discussing animal models and human studies.

This book specifically focuses on Treg-based therapeutics and their targets to manage all known autoimmune rheumatic, central nervous system, bowel, liver, thyroid, kidney, myopathic, skin, blood and blood vessel, and eye diseases and aims to provide a must-have reference for designing therapeutic strategies to treat these autoimmune diseases. Additionally, this book covers vaccine-induced effects on the functioning of Tregs and development of CAR Treg therapy for autoimmune diseases and concludes with current challenges and future prospects of Treg-based therapeutics. This book is carefully designed to meet the requirements of both basic and advanced researchers in the area and provide new dimensions and insight into regulatory T cells’ role in autoimmune disease pathogenesis and therapy.

Cover image
Title page
Table of Contents
Copyright
List of contributors
Foreword
Part I: Regulatory T cells and immune system
Chapter 1. Regulatory T cells and their functions in immune system
Abstract
1.1 Introduction
1.2 Types of Tregs and their origin
1.3 Mechanism of action of Tregs
1.4 Functional aspects of Tregs
1.5 Therapeutic role of Tregs in autoimmune diseases
1.6 Conclusion
Acknowledgments
Conflict of Interest
References
Chapter 2. Regulatory T cells: mechanisms of action
Abstract
2.1 Introduction
2.2 Regulatory T cells
2.3 Mechanisms of action of Treg cells
2.4 Mechanism of Treg cells in cancer
2.5 Mechanism of Treg cells in autoimmunity
2.6 Mechanism of Treg cells in infectious diseases
2.7 Conclusion
Conflict of interest
References
Chapter 3. Regulatory T cells and autoimmunity
Abstract
3.1 Introduction
3.2 Regulatory T cells and inflammatory autoimmune diseases
3.3 Therapeutic modulation of regulatory T cells as a therapy
3.4 Conclusion
Conflict of Interest
Disclosure Statement
References
Further reading
Chapter 4. Sex differences in regulatory T cells during autoimmune disease
Abstract
Abbreviations
4.1 Regulatory T cells: the basics
4.2 T helper Tregs
4.3 Tregs and autoimmune disease
4.4 Autoimmune disease mechanisms
4.5 Sex differences in autoimmune disease
4.6 Sex differences in Tregs and autoimmune disease
4.7 Conclusions
Conflict of interest
Funding
References
Part II: Role of regulatory T cells in rheumatic diseases
Chapter 5. Role of regulatory T cells in pathogenesis and therapeutics of systemic lupus erythematosus
Abstract
5.1 Introduction
5.2 Regulatory T cells
5.3 Implications of regulatory T cells in SLE
5.4 Clinical and experimental therapeutic strategies targeting regulatory T cells
5.5 Conclusions
Conflict of interest
References
Chapter 6. Role of regulatory T cells in the pathogenesis and therapeutics of primary Sjögren’s syndrome
Abstract
6.1 Introduction
6.2 Diagnosis versus classification criteria
6.3 Physiopathology of pSS
6.4 Regulatory T cells and other T cell subsets in pSS
6.5 Treg cells in the treatment of pSS
6.6 Target Treg cells in the pSS
6.7 Conclusion
Conflict of Interest
References
Chapter 7. Role of regulatory T cells in pathogenesis and therapeutics of rheumatoid arthritis and juvenile idiopathic arthritis
Abstract
7.1 Introduction
7.2 Immunosuppressive mechanisms of Treg cells in autoimmunity
7.3 Treg cell alterations in RA/JIA pathogenesis
7.4 Therapeutic potential of Treg cells in RA/JIA
7.5 Challenges of Treg-based therapies
7.6 Conclusion
Funding
Conflict of Interest
References
Chapter 8. Role of regulatory T cells in pathogenesis and therapeutics of psoriatic arthritis
Abstract
8.1 Regulatory T cells
8.2 Psoriatic arthritis
8.3 Regulatory T cells in the treatment of psoriatic arthritis
8.4 Concluding remarks
Acknowledgment
Conflict of interest
References
Chapter 9. Role of regulatory T cells in pathogenesis and therapeutics of spondyloarthritis
Abstract
9.1 Introduction
9.2 Is the TREG’s heterogeneity relevant to SpA?
9.3 SpA-specific impairment of negative immune regulation by Tregs
9.4 TREG’s and intestinal inflammation in SpA
9.5 The strategies to promote the number and function of endogenous Tregs in SpA
9.6 Conclusions and future directions
Conflict of Interest
References
Chapter 10. Role of regulatory T cells in pathogenesis and therapeutics of ankylosing spondylitis
Abstract
10.1 Introduction
10.2 Tregs subset and gene signature
10.3 The genetic bases of Treg dysfunction in ankylosing spondylitis
10.4 Pathogenic Tregs module in inflammatory rheumatic diseases
10.5 Tregs in synovial fluid and peripheral blood: similarities and differences
10.6 New technologies in studying Tregs
10.7 Tregs and treatment for ankylosing spondylitis
10.8 Conclusions and future therapeutic perspectives
Conflict of Interest
References
Part III: Role of regulatory T cells in central nervous system demyelinating autoimmune diseases
Chapter 11. Role of regulatory T cells in pathogenesis and therapeutics of multiple sclerosis
Abstract
Abbreviations
11.1 Introduction
11.2 Role of regulatory T cells in pathogenesis of multiple sclerosis
11.3 Regulatory T cells as a target in MS therapy
11.4 Conclusion
Conflict of interest
References
Chapter 12. Role of regulatory T cells in the pathogenesis and therapeutics of neuromyelitis optica spectrum disorder
Abstract
List of abbreviations
12.1 Introduction
12.2 Neuromyelitis optica spectrum disorder: a rare disease
12.3 Clinical features of neuromyelitis optica spectrum disorder
12.4 Humoral mechanisms in pathogenesis of neuromyelitis optica spectrum disorder
12.5 Regulatory T cells in maintaining self-tolerance
12.6 Role of regulatory T cells in neuromyelitis optica spectrum disorder
12.7 Recently approved therapies to treat neuromyelitis optica spectrum disorder
12.8 Potential of B-cell maturation antigen, chimeric antigen receptor-T cells to treat neuromyelitis optica spectrum disorder
12.9 Potential of regulatory T cells to treat neuromyelitis optica spectrum disorder
12.10 Other potential therapies to induce or expand regulatory T cells
12.11 Conclusions
Conflict of interest
References
Part IV: Role of regulatory T cells in peripheral nerve, muscle and neuromuscular autoimmune diseases
Chapter 13. Role of regulatory T cells in pathogenesis and therapeutics of myasthenia gravis
Abstract
13.1 Introduction
13.2 Regulatory T cells’ dysfunction in myasthenia gravis patients and experimental autoimmune myasthenia gravis
13.3 Pathogenesis of myasthenia gravis due to effector and regulatory T cells’ imbalance
13.4 Regulatory T cells and the treatment of myasthenia gravis
13.5 Conclusion
Acknowledgment
Conflict of interest
References
Chapter 14. Role of regulatory T cells in pathogenesis and therapeutics of Guillain–Barré syndrome and experimental autoimmune neuritis
Abstract
14.1 Introduction
14.2 Experimental autoimmune neuritis
14.3 Guillain–Barré syndrome
14.4 Guillain–Barré syndrome: treatment effect on Treg modulation
14.5 Guillain–Barré syndrome: experimental therapies and their modulating effects on Tregs
14.6 Conclusions
Conflict of interest
References
Chapter 15. Role of regulatory T cells in pathogenesis and therapeutics of chronic inflammatory demyelinating polyradiculoneuropathy
Abstract
15.1 Chronic inflammatory demyelinating polyradiculoneuropathy (definition, epidemiology, and risk factors)
15.2 Etiopathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy
15.3 Clinical features of chronic inflammatory demyelinating polyradiculoneuropathy
15.4 Diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy
15.5 Differential diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy
15.6 Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy
15.7 Therapy for chronic inflammatory demyelinating polyradiculoneuropathy
15.8 Conclusion
Conflict of interest
References
Chapter 16. Role of regulatory T cells in pathogenesis and therapeutics of dermatomyositis and polymyositis
Abstract
16.1 Introduction
16.2 Genetic and environmental factors
16.3 Clinical features
16.4 Diagnosis
16.5 Pathogenesis
16.6 Regulatory T cells in polymyositis and dermatomyositis
16.7 Treatment of polymyositis and dermatomyositis
16.8 Conclusion
Conflict of interest
References
Part V: Role of regulatory T cells in inflammatory bowel diseases
Chapter 17. Role of regulatory T cells in pathogenesis and therapeutics of Crohn’s disease and ulcerative colitis
Abstract
17.1 Introduction
17.2 Pathogenesis of CD and UC
17.3 Intestinal Treg
17.4 Treg-enhancing therapies in IBD
17.5 Conclusion and future direction
Conflict of interest
References
Chapter 18. Role of regulatory T cells in pathogenesis and therapeutics of celiac disease
Abstract
18.1 Introduction
18.2 Role of immune cells in celiac disease
18.3 Regulatory T cells and their markers involved in celiac disease
18.4 Altered Treg cell numbers and function in celiac disease
18.5 Mechanisms involved in Treg-mediated suppression of celiac disease
18.6 Role of Tregs in therapeutics of celiac disease
18.7 Role of gluten-specific Tregs in therapeutics of celiac disease
18.8 Conclusions
Conflict of Interest
References
Part VI: Role of regulatory T cells in autoimmune liver diseases
Chapter 19. Role of regulatory T cells in the pathogenesis and therapeutics of autoimmune hepatitis
Abstract
Abbreviations
19.1 Autoimmune hepatitis
19.2 Autoimmune hepatitis liver damage
19.3 Tregs: a brief overview
19.4 Mechanisms of Tregs-mediated suppression
19.5 Tregs in autoimmune hepatitis
19.6 Future immunotherapy avenues
19.7 Conclusions
Funding
Competing interest statement
References
Chapter 20. Role of regulatory T cells in pathogenesis and therapeutics of primary biliary cholangitis and primary sclerosing cholangitis
Abstract
20.1 Introduction
20.2 Primary biliary cholangitis
20.3 Primary sclerosing cholangitis
20.4 Regulatory T cells
20.5 Tregs’ localization and function in intra-hepatic immune homeostasis
20.6 Role of Tregs in PBC and PSC
20.7 Potential of Tregs as therapeutic option for PBC and PSC
20.8 Conclusion
Conflict of Interest
References
Part VII: Role of regulatory T cells in autoimmune thyroid diseases
Chapter 21. Role of regulatory T cells in pathogenesis and therapeutics of Hashimoto’s thyroiditis
Abstract
21.1 Introduction
21.2 Immune disease: the part played by regulatory T cells
21.3 Role of regulatory T cells in autoimmune thyroid diseases
21.4 Hashimoto’s thyroiditis
21.5 Regulatory T cells in treatment and recommendation for HT
21.6 Conclusion
Conflict of Interest
References
Chapter 22. Role of regulatory T cells in pathogenesis and therapeutics of Graves’ disease and Graves’ orbitopathy
Abstract
22.1 Regulatory T cells and autoimmunity
22.2 Graves’ disease
22.3 Graves’ orbitopathy
22.4 Th17/Treg interplay and novel players
22.5 Conclusion
Conflict of Interest
References
Part VIII: Role of regulatory T cells in autoimmune lung & kidney diseases
Chapter 23. Role of regulatory T cells in pathogenesis and therapeutics of Goodpasture’s syndrome (anti-glomerular basement membrane disease)
Abstract
23.1 Introduction
23.2 Regulatory T cells
23.3 Mechanisms of Treg suppressive action
23.4 Role of regulatory T cells in the pathogenesis of Goodpasture’s syndrome
23.5 Targeted-Tregs therapies in Goodpasture’s syndrome
23.6 Conclusion
Acknowledgment
Conflict of interest
References
Chapter 24. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune glomerulonephritis (IgA vasculitis and IgA nephropathy)
Abstract
24.1 Introduction
24.2 Treg cell marker–Foxp3
24.3 Differentiation and function of Treg cells
24.4 Function of Treg cells
24.5 Treg cells and autoimmune diseases
24.6 Treg and IgA vasculitis
24.7 Treg and IgA nephropathy
24.8 The application of Treg cell therapy in the realm of autoimmune disorders (IgAN and IgAV)
24.9 Conclusions
Conflict of Interest
References
Part IX: Role of regulatory T cells in autoimmune skin diseases
Chapter 25. Role of regulatory T cells in pathogenesis and therapeutics of vitiligo
Abstract
25.1 Introduction
25.2 Pathogenesis of vitiligo
25.3 Therapeutic strategies targeting Treg cells in vitiligo
25.4 Challenges and limitations
25.5 Future directions
25.6 Conclusion
Conflict of Interest
References
Chapter 26. Role of regulatory T cells in pathogenesis and therapeutics of psoriasis
Abstract
26.1 Introduction
26.2 Regulatory T cells
26.3 Regulatory T cells in the skin
26.4 Regulatory T cells in pathogenesis of psoriasis
26.5 Impact of existing psoriasis therapies on regulatory T cells
26.6 Available biologics and treatments to target regulatory T cells in psoriasis
26.7 Future perspectives
26.8 Conclusion
Conflict of Interest
References
Chapter 27. Role of regulatory T cells in pathogenesis and therapeutics of atopic dermatitis
Abstract
27.1 Introduction
27.2 Pathogenesis of atopic dermatitis
27.3 Regulatory T cells
27.4 Role of regulatory T cells in pathogenesis of atopic dermatitis
27.5 Role of regulatory T cells in therapeutics of atopic dermatitis
27.6 Conclusion
Conflict of interest
References
Further reading
Chapter 28. Role of regulatory T cells in pathogenesis and therapeutics of alopecia areata
Abstract
28.1 Introduction
28.2 Pathophysiology of alopecia areata
28.3 Altered immune response in alopecia areata
28.4 Regulatory T cells in alopecia areata
28.5 Antigen-specific Treg cells in alopecia areata
28.6 Therapeutic potential of Tregs in alopecia areata
28.7 Conclusion
Conflict of interest
References
Chapter 29. Role of regulatory T cells in pathogenesis and therapeutics of pemphigus vulgaris and bullous pemphigoid
Abstract
29.1 Introduction
29.2 Bullous pemphigoid
29.3 Epidemiology of pemphigus vulgaris and bullous pemphigoid
29.4 Genetic predisposition (human leukocyte antigen restriction in pemphigus and bullous pemphigoid)
29.5 Humoral and cell-mediated immunity
29.6 Genesis of regulatory T cells
29.7 Potential regulatory network of autoaggressive T cells and regulatory T cells in pemphigus
29.8 Correlation of Th17 and Treg cells in pemphigus
29.9 Characterization of surface markers of Tregs
29.10 Indian study on pemphigus vulgaris patients
29.11 Therapeutic challenges
29.12 Current and new immunotherapies for bullous pemphigoid
29.13 Conclusion
Conflict of Interest
References
Chapter 30. Role of regulatory T cells in pathogenesis and therapeutics of scleroderma (systemic sclerosis)
Abstract
30.1 Introduction
30.2 Immunological tolerance defects in systemic sclerosis
30.3 Innate immune cells, soluble products, and receptors in systemic sclerosis
30.4 T cells and adaptive immune function in systemic sclerosis
30.5 B cells and humoral immune response
30.6 Mechanisms of systemic sclerosis pathogenesis
30.7 T cell therapeutic targeting in systemic sclerosis
30.8 Conclusion
Conflict of interest
References
Part X: Role of regulatory T cells in autoimmune blood & blood vessel disorders
Chapter 31. Role of regulatory T cells in pathogenesis and therapeutics of primary antiphospholipid syndrome (Hughes syndrome)
Abstract
31.1 Introduction
31.2 Antiphospholipid syndrome
31.3 Pathogenesis of antiphospholipid syndrome
31.4 Tregs and immune tolerance
31.5 Prevalence of Treg cells in antiphospholipid syndrome
31.6 Th17/Treg ratio in antiphospholipid syndrome
31.7 Follicular regulatory T cells in antiphospholipid syndrome
31.8 Humoral immunoregulation in antiphospholipid syndrome
31.9 aPL and Treg cells in infertility
31.10 Tolerogenic dendritic cells and their link with Tregs in antiphospholipid syndrome
31.11 Tolerogenic DNA vaccines in antiphospholipid syndrome
31.12 Conclusion
Conflict of interest
References
Chapter 32. Role of regulatory T cells in the pathogenesis and therapeutics of Kawasaki disease
Abstract
32.1 Introduction
32.2 Immune regulation is the most important efferent arm of the immune response in pediatrics: physiology in healthy children and physiopathology in Kawasaki disease
32.3 Regulatory T cells in therapeutics of Kawasaki disease: future directions
32.4 Conclusion
Conflict of Interest
References
Further reading
Chapter 33. Role of regulatory T cells in pathogenesis and therapeutics of Behçet disease
Abstract
Abbreviations
33.1 Introduction
33.2 An overview of the pathophysiology of Behcet disease
33.3 Regulatory T cells and aphthous stomatitis
33.4 Regulatory T cells and genital Behcet disease
33.5 Regulatory T cells and ocular Behcet disease
33.6 Regulatory T cells and cutaneous Behcet disease
33.7 Regulatory T cells and articular involvement of Behcet disease
33.8 Regulatory T cells and neuro-Behcet disease
33.9 Regulatory T cells and intestinal Behcet disease
33.10 Regulatory T cells and cardiovascular Behcet disease
33.11 Regulatory T cells and renal Behcet disease
33.12 Therapeutic aspects of regulatory T cells in Behcet disease
33.13 Conclusion
Conflict of interest
References
Chapter 34. Role of regulatory T cells in pathogenesis and therapeutics of immune thrombocytopenia
Abstract
34.1 Introduction
34.2 T cell imbalance in immune thrombocytopenia
34.3 Mechanism of action of cytotoxic T cells in immune thrombocytopenia
34.4 NK cells and T lymphocytes’ dysregulation in immune thrombocytopenia
34.5 Extrinsic cellular suppression in immune thrombocytopenia
34.6 Mechanisms of regulatory T cells in immune thrombocytopenia
34.7 Dysregulated Tregs in patients with immune thrombocytopenia
34.8 The role of the Th1/Th2 balance in immune thrombocytopenia
34.9 Immune-mediated megakaryocyte maturation abnormality in immune thrombocytopenia
34.10 Mechanisms of T cell anergy in immune thrombocytopenia
34.11 CD8+ T cell activation and target cell interaction
34.12 Other CD8+ T cell abnormalities in immune thrombocytopenia
34.13 CD8+ T cells at sites of platelet destruction and production
34.14 Evidence for CD8+ T cell-mediated platelet destruction in immune thrombocytopenia
34.15 Regulatory T cells in therapeutics for immune thrombocytopenia
34.16 Conclusion
Conflict of Interest
References
Chapter 35. Role of regulatory T cells in pathogenesis and treatment of antineutrophil cytoplasmic antibody-associated vasculitis
Abstract
35.1 Introduction
35.2 Regulatory T cells in ANCA-associated vasculitis: role of T cells in pathogenesis
35.3 Regulatory T cells in AAV
35.4 Regulatory T cells abnormalities in other forms of systemic vasculitis
35.5 Cell therapy with regulatory T cells
35.6 Conclusion
Acknowledgment
Conflict of Interest
References
Chapter 36. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune hemolytic anemia
Abstract
Abbreviations
36.1 Introduction
36.2 Epidemiology
36.3 Classification of autoimmune hemolytic anemia
36.4 Pathophysiology of autoimmune hemolytic anemia
36.5 Major blood group antigens and antibodies involved in autoimmune hemolytic anemia
36.6 Etiology of immune response in autoimmune hemolytic anemia
36.7 Factors affecting the onset of autoimmunity in autoimmune hemolytic anemia
36.8 Mechanism of immune-mediated lysis of erythrocytes
36.9 Treatment of autoimmune hemolytic anemia
36.10 Conclusion
Acknowledgment
Conflict of Interest
References
Part XI: Role of regulatory T cells in autoimmune eye diseases and type 1 diabetes mellitus
Chapter 37. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune uveitis
Abstract
37.1 Introduction
37.2 The immune system and immune privilege
37.3 Role of regulatory T cells in pathogenesis of AIU
37.4 Treg-based therapeutic advancement in AIU
37.5 Conclusion
Conflict of interest
References
Chapter 38. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune retinopathy
Abstract
38.1 Introduction
38.2 Role of regulatory T cells in AIR
38.3 Role of regulatory T cells in the management of AIR
38.4 Conclusion
Conflict of Interest
References
Chapter 39. Role of regulatory T cells in the pathogenesis and therapeutics of type 1 diabetes mellitus
Abstract
39.1 Introduction
39.2 Formation and components of regulatory T cells
39.3 Role of regulatory T cells in the pathogenesis of T1DM
39.4 Role of Tregs’ associated genes in the pathogenesis of T1DM
39.5 Role of Tregs in therapeutics of T1DM
39.6 Conclusions
Conflict of Interest
References
Part XII: Current challenges and future prospects in research towards regulatory T cells based therapeutics in autoimmune diseases
Chapter 40. Vaccine-induced effects on regulatory T cell function: autoimmune perspective
Abstract
40.1 Introduction
40.2 Dynamics of regulatory T cells after vaccination
40.3 Control of vaccine-specific responses by Tregs in secondary lymphoid organs
40.4 Effect of Tregs on vaccine efficacy
40.5 Approaches for Tregs modulation to improve vaccine efficacy
40.6 Immune-related adverse events associated with Tregs modulation
40.7 Conclusion
Acknowledgment
Conflict of interest
References
Chapter 41. Probiotic interventions for regulatory T cells’ induction in autoimmune diseases
Abstract
41.1 Introduction
41.2 Major approaches of Tregs, immune system, and probiotics
41.3 Mechanisms involved in Treg induction by probiotics
41.4 Probiotics and regulatory T cells’ induction in autoimmune diseases
41.5 Conclusion
Conflict of interest
References
Chapter 42. CAR Treg-based therapeutics for autoimmune diseases
Abstract
42.1 Introduction
42.2 CAR structure and CAR T generation
42.3 CAR T structure used for B cell malignancies
42.4 Why is CD19 a preferable target in ALL?
42.5 CAR T therapy for autoimmune diseases
42.6 CAR Treg therapy for ADs
42.7 Conclusion
Conflict of interest
References
Further reading
Chapter 43. Current challenges and future prospects of regulatory T-cell based therapeutics in autoimmune diseases
Abstract
43.1 Introduction
43.2 Autoimmune disease
43.3 Regulatory T cells: mechanisms, functions, and therapeutic potential in autoimmune and inflammatory diseases
43.4 Role of cell therapy in different disorders
43.5 Challenges in clinical applications of Tregs
43.6 Future prospects of Tregs
43.7 Conclusion
Conflict of Interest
References
Index

Mitesh Kumar Dwivedi

Mitesh Kumar Dwivedi, PhD, is an assistant professor of microbiology at the C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University. He has published 63 research papers and 46 book chapters, edited 8 books, and serves as an editorial board member and reviewer of many international journals. He has an h-index of 25 with 2261 citations for his research papers. His research interests include investigation of immunogenetic, autoimmune, and therapeutic aspects of vitiligo, rheumatoid arthritis, sickle cell disease, and the role of probiotics in amelioration of autoimmune diseases. He is a recipient of numerous honors: DST-SERB Core Research Grant (2022), SERB-SIRE International Research Fellowship (2022), Best Researcher Award (2020), INSA Visiting Scientist Award (2019), DST-SERB Early Career Research Award (2018), Young Scientist Awards (2011, 2013, and 2018), and all India rank “32” in CSIR-NET national examination (2011; Life Sciences). He has successfully completed six research projects as principal investigator from national funding agencies: SERB-DST, GUJCOST, UTU, and Neo Sciences & Research Solutions Pvt. Ltd. and guided students for their doctoral and master degrees.

Affiliations and expertise

Assistant Professor of Microbiology, C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University, India

DeLisa Fairweather

DeLisa Fairweather, PhD, is a professor of medicine and immunology and director of translational research in the Department of Cardiovascular Medicine at Mayo Clinic in Jacksonville, Florida, studying sex/gender differences in cardiovascular and autoimmune diseases, including myocarditis. Her research has been continuously funded by the National Institutes of Health (NIH), the American Heart Association (AHA), BARDA, and others. She serves on NIH, the Board of the Atwal Clinic and Mayo Clinic Mitochondrial Research Center, and formerly on the Board of the Myocarditis Foundation. She was a leader of the US FDA Mayo-led Expanded Access Program during the COVID-19 pandemic. She has served on the National Academies of Sciences, Engineering, and Medicine (NASEM) committee making recommendations to NIH and Congress on the autoimmune disease portfolio of NIH and on the NASEM committee to examine side effects of COVID-19 vaccines. She is a member of the Scientific Advisory Board for the Autoimmune Registry as well as the Organization for the Study of Sex Differences (OSSD).

Affiliations and expertise

Director of Translational Research Department Cardiovascular Medicine, Mayo Clinic, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health